Xcout Intel
ArsenalBio
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Subscribe to see ArsenalBio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ArsenalBio at a glance
ArsenalBio is a biotech company. Xcout tracks 11 named people at ArsenalBio, including Bee Nguyen (Chief People Officer). Xcout recorded 1 job posting from ArsenalBio in the last 90 days.
ArsenalBio leadership
- Bee NguyenChief People Officer
- Gift NgarmchamnanrithChief Medical Officer
- Tim SirichokeChief Technical Operations Officer
- Irene PleasureGeneral Counsel & Corporate Secretary
- Ken DrazanChairman, CEO, Co-Founder
- W. Nicholas HainingChief Scientific Officer
5 more named people on record for ArsenalBio, with roles, board committees and tenure — see the full roster →
Hiring at ArsenalBio
Xcout recorded 1 job posting from ArsenalBio in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see ArsenalBio's hiring signals →
ArsenalBio competitors
A few of ArsenalBio's closest competitors — see the full list of competitors and alternatives →
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Get ArsenalBio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ArsenalBio in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access